Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 5c; Guides In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 5c; Guides In-Line
May 11, 2016 9:05 AM EDT
UBS analyst, Marc Goodman, raised his PT on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $168 from $162 as high single digit revenue growth was basically in line with expectations but EPS of $2.26 fell short of consensus $2.30. The Street was a little low on spending but the analyst thinks investors will quickly look through the slight EPS miss because of the newly disclosed Xyrem patent settlements out to 2025, which is better than expected. The firm... More
May 11, 2016 6:17 AM EDT
Mizuho Securities upgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Neutral to Buy with a price target of $193.00 (from $137.00) on Xyrem Settlements.
Analyst Irina Koffler commented, "Jazz's announcement of its late 2025 Xyrem settlements was the upgrade signal we were looking for. We modeled Xyrem... More
